Shares of Thyrocare Technologies tumbled nearly 8% on Thursday as its promoter and parent company Docon Technologies offloaded nearly 10% stake through a block deal. Thyrocare shares tumbled to an intraday low of Rs 594 apiece on Thursday.

The stock later recovered some losses, trading around 4% lower at Rs 614 apiece in the afternoon. 58 crore shares of Thyrocare in market trade, the company said in an exchange filing.

92. Following the aforesaid transaction, Docon continues to be a promoter and holding company of Thyrocare, the company clarified.

7 crore shares, or 61% stake in the company, as on June 30, 2026, according to data on the company’s shareholding pattern on NSE. Another 20% stake was held by 13 mutual funds, including Nippon Life India, ICICI Prudential and others.

6% stake in the company, as at the end of the April-June quarter of the ongoing financial year 2027. Thyrocare share priceThyrocare shares have gained around 3% in a week and 20% in a month, being up more than 37% in 2026 so far.

The stock has overall gained 34% in one year. In the longer term, Thyrocare shares have delivered stellar 221% returns over three years, and 38% over five years.

The company currently has a market capitalisation of around Rs 9,797 crore. Thyrocare Q1 earningsThyrocare reported a 24% year-on-year growth in consolidated revenue to Rs 240 crore for the first quarter of FY27.

EBITDA grew 34% to Rs 77 crore, while profit after tax also increased 34% YoY to Rs 51 crore. 2 million tests, up 28% YoY, making it the largest diagnostic test volume processor in India.

”“During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expansion of the test menu underway,” he added..